Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT01428739
First received: October 21, 2010
Last updated: October 1, 2014
Last verified: October 2014
  Purpose

Correlation between MRS and Tumor Response Therapy in Breast Cancer.


Condition Intervention
Breast Cancer
Device: MRS

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • MRS Correlation with Treatment Response [ Time Frame: Up to One Year ] [ Designated as safety issue: Yes ]
    measuring choline, water and fat levels by proton magnetic resonance spectroscopy in breast tumors in response to treatment


Secondary Outcome Measures:
  • Correlation with Tumor Stage [ Time Frame: Up to One year ] [ Designated as safety issue: Yes ]

Enrollment: 8
Study Start Date: December 2007
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: MRS
    Procedure
    Other Name: Philips 3 Tesla MRI Scanner
Detailed Description:

Correlation between MRS (Magnetic Resonance Spectroscopy and Tumor Response to Radiation in Breast Cancer

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosed Breast cancer
  • Patient is 18 years or older
  • Karnofsky performance score > 70
  • No previously irradiated or recurrent breast cancer
  • No contraindication to MRS/MRI
  • Signed informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01428739

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Nadeem Pervez, MBBS, FFRRCSI, FRCPC Cross Cancer Institute
  More Information

No publications provided

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT01428739     History of Changes
Other Study ID Numbers: 23701
Study First Received: October 21, 2010
Last Updated: October 1, 2014
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
cancer
MRS
Treatment response

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases

ClinicalTrials.gov processed this record on November 27, 2014